Percutaneous Coronary Intervention for Coronary Bifurcation Lesions: Latest Evidence

Tan, Sean; Ramzy, J.; Burgess, Sonya; Zaman, Sarah

doi:10.1007/s11936-020-0806-4

Cited by 14 publications

(12 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dedicated bifurcation stents can be chosen for this procedure as they make it possible for the operator to perform the lesion stenting without the need to rewire the side branch [140]. This alternative to complex two-stent strategies has led to similar clinical outcomes as the conventional provisional stenting approach [141]. [110]; (e) Zn stent with Omega design [110]; (f) Mg alloy AE21 stents [101]; (g) main vessel stent with side-branch scaffold [140].…”

Section: Novel Platformsmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

One of the leading causes of morbidity and mortality worldwide is coronary artery disease, a condition characterized by the narrowing of the artery due to plaque deposits. The standard of care for treating this disease is the introduction of a stent at the lesion site. This life-saving tubular device ensures vessel support, keeping the blood-flow path open so that the cardiac muscle receives its vital nutrients and oxygen supply. Several generations of stents have been iteratively developed towards improving patient outcomes and diminishing adverse side effects following the implanting procedure. Moving from bare-metal stents to drug-eluting stents, and recently reaching bioresorbable stents, this research field is under continuous development. To keep up with how stent technology has advanced in the past few decades, this paper reviews the evolution of these devices, focusing on how they can be further optimized towards creating an ideal vascular scaffold.

show abstract

Section: Novel Platformsmentioning

confidence: 99%

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Percutaneous coronary intervention (PCI) is an important approach for the definitive diagnosis and revascularization of patients with ACS. 1 , 2 In patients undergoing PCI, contrast-induced nephropathy (CIN) has become a serious complication and it is closely related to clinical adverse events, such as an increased incidence of renal failure and increased short- and long-term mortality rates. 3 , 4 CIN refers to an increase in serum creatinine levels by 25% or an increase in the absolute value by more than 44.2 μmol/L after application of a contrast agent.…”

Section: Introductionmentioning

confidence: 99%

Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysis

et al. 2021

View full text Add to dashboard Cite

Objective Contrast-induced nephropathy (CIN) is a serious complication in patients with acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). This study aimed to analyze the potential risk factors for CIN in patients undergoing PCI. Methods Patients with ACS who underwent PCI treatment from January 2017 to January 2020 were selected. The patients’ characteristics and medical information were collected and compared. Results A total of 1331 patients undergoing PCI were included. The incidence of CIN was 15.33%. Logistic regression analyses showed that a left ventricular ejection fraction ≤45% (odds ratio [OR] 4.18, 95% confidence interval [CI] 1.10–7.36), serum creatinine levels ≤60 μmol/L (OR 3.03, 95% CI 1.21–5.57), age ≥65 years (OR 2.75, 95% CI 1.32–4.60), log N-terminal pro-B-type natriuretic peptide levels ≥2.5 pg/mL (OR 2.31, 95% CI 1.18–5.13), uric acid levels ≥350 μmol/L (OR 2.29, 95% CI 1.04–5.30), emergency percutaneous intervention (OR 1.35, 95% CI 0.34–3.12), and triglyceride levels ≤1.30 mmol/L (OR 1.10, 95% CI 0.01–2.27) were independent risk factors for CIN in patients who underwent PCI. Conclusions Early prevention is required to reduce the occurrence of CIN in patients who undergo PCI and have risk factors for CIN.

show abstract

“…With the continuous improvement of life quality, the global cardiovascular disease prevalence is in a continuous rising stage, and the mortality of cardiovascular disease ranks first, which is higher than that of tumors and other diseases [1,2]. The proportion of died patients with coronary heart disease (CHD) among the total number of deaths has increased from 8.6% in 1990 to 15.2% in 2013 [3]. With the intensification of the aging process, the morbidity and mortality of CHD in various countries will continue to increase, which seriously threatens the health of the people and brings a heavy social and economic burden [4].…”

Section: Introductionmentioning

confidence: 99%

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do

Wang

Qiao

Wang

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Percutaneous coronary intervention (PCI) is a common treatment for patients with coronary heart disease, and intra-stent restenosis (ISR) is a serious complication after PCI. It’s necessary to identify the potential risk factors to provide evidence for the prevention of ISR. Methods The patients who underwent coronary angiography 1 year after PCI in our hospital from January 2017 to May 2019 were selected. The characteristics and results of clinical examination of ISR and no-ISR patients were compared, Multivariate logistic regression analyses were performed to identify the risk factors. Results A total of 209 patients were included, the incidence of ISR after PCI was 30.62%. There were significant differences on the hypertension, diabetes, number of coronary artery lesions, reasons for stent implantation, the diameter of stent, the length of stent and stent position between ISR group and no-ISR patients (all p < 0.05). The LDL-C in ISR groups was significantly higher than that of no-ISR group (p = 0.048), there were no significant differences between two groups in FPG, TG, TC, HDL-C, Apo A1, Apo B, LP-a and glycated haemoglobin (all p > 0.05). The hypertension (OR 4.30, 95% CI 1.12–9.34), diabetes (OR 5.29, 95% CI 1.25–9.01), number of coronary artery lesions ≥ 2 (OR 4.84, 95% CI 1.21–9.55), LDL-C ≥ 1.9 mmol/L (OR 5.93, 95% CI 2.29–10.01), unstable angina (OR 2.92, 95% CI 1.20–4.55), left anterior descending artery (OR 4.01, 95% CI 1.73–7.58), diameter of stent ≥ 3 mm (OR 5.42, 95% CI 1.24–10.84), the length of stent > 20 mm (OR 3.06, 95% CI 1.19–5.22) were the independent risk factor for ISR (all p < 0.05). Conclusion It is necessary to take preventive measures against these risk factors to reduce ISR, and studies with larger sample size and longer follow-up on this issue are needed in the future.

show abstract

Percutaneous Coronary Intervention for Coronary Bifurcation Lesions: Latest Evidence

Cited by 14 publications

References 60 publications

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysis

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do

Contact Info

Product

Resources

About